Aligos Therapeutics, Inc. (ALGS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Aligos Therapeutics, Inc. (ALGS) Healthcare & Pipeline Overview

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to addressing unmet medical needs in viral and liver diseases like chronic hepatitis B and NASH. Their pipeline features multiple clinical trials and strategic collaborations, positioning them within the competitive biotechnology sector.

What Is the Investment Thesis for ALGS?

Aligos Therapeutics operates in the high-growth biotechnology sector, focusing on treatments for viral and liver diseases. The company's pipeline, featuring ALG-010133 and ALG-000184 for CHB, represents a significant value driver. Positive outcomes from ongoing Phase Ib and Phase I clinical trials could serve as major catalysts. Strategic collaborations with Luxna Biotech, Emory University, Katholieke Universiteit Leuven, and Merck provide additional validation and potential revenue streams. However, the company's negative profit margin of -1919.7% and negative free cash flow of $-0.07B highlight financial risks. The high beta of 2.75 indicates significant volatility. Successful clinical trials and partnership milestones are essential for driving shareholder value.

Based on FMP financials and quantitative analysis

ALGS Key Highlights

Market Cap of $33.0M reflects the company's current valuation in the biotechnology sector.

• P/E ratio of -1.38 indicates the company is currently unprofitable.
• Profit Margin of -1919.7% shows significant losses relative to revenue.
• Gross Margin of 89.0% suggests strong potential profitability if operating expenses are managed effectively.
• Free Cash Flow of $-0.07B indicates the company is burning cash and may need additional financing.

Who Are ALGS's Competitors?

ALGS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ALGS's Key Strengths?

Innovative pipeline of drug candidates targeting unmet medical needs.

• Strategic collaborations with leading research institutions and pharmaceutical companies.
• Experienced management team with expertise in drug development.
• Proprietary technology platforms for developing novel therapeutics.

What Are ALGS's Weaknesses?

High operating losses and negative free cash flow.

• Dependence on successful clinical trial outcomes.
• Limited commercialization experience.
• Small company size with limited resources.

What Could Drive ALGS Stock Higher?

Phase Ib clinical trial results for ALG-010133 in chronic hepatitis B.

• Phase I clinical trial results for ALG-000184 in chronic hepatitis B.
• Phase 1a/1b clinical trial progress for ALG-055009 in non-alcoholic steatohepatitis (NASH).
• Advancement of siRNA drug candidate ALG-125755 through preclinical and clinical development.
• Progress in collaborations with Luxna Biotech, Emory University, Katholieke Universiteit Leuven, and Merck.

What Are the Key Risks for ALGS?

Financial-distress signal — its Altman Z-Score of -16.01 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or unexpected safety issues with drug candidates.
• Regulatory delays or rejection of drug approval applications.
• Competition from established pharmaceutical companies and other biotech firms.
• High operating losses and need for additional financing.
• Patent disputes and intellectual property infringement.

What Are the Growth Opportunities for ALGS?

• Advancement of ALG-010133 in CHB Treatment: ALG-010133, currently in Phase Ib clinical trials, targets chronic hepatitis B, a market with a significant unmet need. Successful trial outcomes and subsequent regulatory approval could lead to substantial revenue.
• Development of ALG-000184 for CHB: ALG-000184, a capsid assembly modulator in Phase I clinical trials, represents another growth opportunity in the CHB space. Positive clinical data could position it as a novel treatment option. The CHB market is driven by the chronic nature of the disease and the need for more effective therapies.
• Progression of ALG-055009 for NASH: ALG-055009, a small molecule THR-ß agonist in Phase 1a/1b trials, targets non-alcoholic steatohepatitis (NASH). The NASH market is expected to grow rapidly due to the increasing prevalence of obesity and diabetes. Successful development could provide Aligos with a significant share of this expanding market.
• Expansion of siRNA Drug Candidate ALG-125755: The siRNA drug candidate ALG-125755, along with ALG-125097 and ALG-125819, which have demonstrated potent inhibition of HBsAg release from HBV-infected cells, presents a growth opportunity in HBV treatment. Further development and clinical trials could lead to a novel therapeutic approach.
• Strategic Collaborations and Licensing Agreements: Aligos' collaborations with Luxna Biotech, Emory University, Katholieke Universiteit Leuven, and Merck provide access to new technologies and markets. These partnerships can accelerate drug development and commercialization, enhancing the company's growth prospects. Licensing agreements also provide potential revenue streams through royalties and milestone payments.

What Are ALGS's Competitive Advantages?

• Proprietary drug candidates targeting specific viral and liver diseases.
• Strategic collaborations with leading research institutions and pharmaceutical companies.
• Intellectual property protection through patents and exclusive licenses.

What Does ALGS Do?

Aligos Therapeutics, Inc. was founded in 2018 and is headquartered in South San Francisco, California. The company focuses on developing novel therapeutics to address unmet medical needs in viral and liver diseases. Their lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer currently in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB). Another key candidate is ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials for CHB. Aligos is also developing ALG-020572, an antisense oligonucleotide designed to prevent HBsAg translation and secretion, and ALG-055009, a small molecule THR-ß agonist in Phase 1a/1b for the treatment of non-alcoholic steatohepatitis (NASH). The company's pipeline also includes siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, which have demonstrated potent inhibition of HBsAg release from HBV-infected cells. Aligos has established collaborations with Luxna Biotech Co., Ltd., Emory University, Katholieke Universiteit Leuven, and Merck to develop and commercialize its products and technologies.

What Products and Services Does ALGS Offer?

• Develop novel therapeutics for viral diseases.
• Focus on unmet medical needs in liver diseases.
• Advance ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer, for chronic hepatitis B (CHB) treatment.
• Develop ALG-000184, a capsid assembly modulator, for CHB treatment.
• Develop ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion.
• Develop ALG-055009, a small molecule THR-ß agonist for non-alcoholic steatohepatitis (NASH) treatment.
• Develop siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, which demonstrated potent inhibition of HBsAg release from HBV-infected cells.

How Does ALGS Make Money?

• Develop and commercialize novel therapeutics for viral and liver diseases.
• Generate revenue through licensing agreements and collaborations with other companies.
• Advance drug candidates through clinical trials to obtain regulatory approval and market access.

What Industry Does ALGS Operate In?

Aligos Therapeutics operates within the competitive biotechnology industry, which is characterized by high R&D spending, regulatory hurdles, and potential for significant returns. The company focuses on viral and liver diseases, aligning with the growing need for innovative treatments in these areas. The hepatitis B and NASH markets are substantial, with increasing prevalence and limited treatment options. Competition includes established pharmaceutical companies and other biotech firms developing similar therapies. Aligos' success depends on its ability to navigate the complex regulatory landscape and demonstrate clinical efficacy.

Who Are ALGS's Key Customers?

• Patients suffering from chronic hepatitis B (CHB).
• Patients suffering from non-alcoholic steatohepatitis (NASH).
• Pharmaceutical companies through licensing and collaboration agreements.

Aligos Therapeutics, Inc. (ALGS) Valuation Context

Valued at $33.0M, ALGS is classified as a micro-cap stock. Analyst price targets span from $20.00 to $20.00, with a consensus of $20.00. At the current price of $5.33, that implies approximately 275% upside potential. Relative to its peer group, ALGS's quantitative score of 19/100 is below the peer average of 77/100.

ALGS Revenue & Earnings Trend

In Jun 2026, ALGS generated $27.8M in top-line revenue, marking a sequential increase of 881.6%. The company recorded a net loss of $1.5M, with diluted EPS of $-0.14. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, ALGS averaged $-1.83 in diluted EPS.

Company Profile

Aligos Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Lawrence Blatt. ALGS has traded publicly since 2020.

Key Financial Metrics

A current ratio of 2.56 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -152.3%, the inverse of the P/E and a quick read on earnings relative to price.

Aligos Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -16.01 places it in the distress zone, a signal of elevated financial risk.

Aligos Therapeutics, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 39.0% below estimates on average.

Wall Street analysts project Aligos Therapeutics, Inc. revenue of about $36.0M for fiscal 2026, with EPS near $-6.30. The estimate reflects 5 contributing analysts.

Over the past six months, Aligos Therapeutics, Inc. insiders filed 6 SEC Form 4 transactions — 0 sales and 6 purchases. On net that is roughly 35K shares acquired (about $193K) — insiders putting money in tends to read as conviction.

ALGS Financials

ALGS Latest News

ALGS Analyst Consensus

ALGS MoonshotScore

What Investors Ask About Aligos Therapeutics, Inc. (ALGS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources